Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor

British Journal of Dermatology

Volumn 173, Issue 4, 2015, Pages 989-997

  Punwani, N ^a   Burn, T ^a   Scherle, P ^a   Flores, R ^a   Shi, J ^a   Collier, P ^a   Hertel, D ^a   Haley, P ^a   Lo, Y ^a   Waeltz, P ^a   Rodgers, J ^a   Shepard, S ^a   Vaddi, K ^a   Yeleswaram, S ^a   Levy, R ^a   Williams, W ^a   Gottlieb, A B ^b  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYTOKERATIN 16; GLYCOPROTEIN P 15095; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; MESSENGER RNA; RANTES; RUXOLITINIB; STAT3 PROTEIN; STAT5 PROTEIN; BIOLOGICAL MARKER; CYTOKINE; DERMATOLOGICAL AGENT; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; OINTMENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ALLERGY; APPLICATION SITE IRRITATION; ARTICLE; BODY SURFACE; CHRONOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION AT STEADY-STATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DERMATITIS; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMIS HYPERPLASIA; FEMALE; GENE EXPRESSION; GENERAL HEALTH STATUS ASSESSMENT; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPESTHESIA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEUKOPENIA; MALE; MULTICENTER STUDY; OPEN STUDY; PARANOID SCHIZOPHRENIA; PHYSICIANS GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS VULGARIS; RETICULOCYTOSIS; SEASONAL ALLERGY; SKIN BIOPSY; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; TH17 CELL; TOPICAL TREATMENT; TREATMENT DURATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OINTMENT; PSORIASIS; TH1 CELL; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; BIOMARKERS; CYTOKINES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; OINTMENTS; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRAZOLES; STAT3 TRANSCRIPTION FACTOR; TH1 CELLS; TH17 CELLS; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946206331     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13994     Document Type: Article

References (18)

1. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-50.
2. Goodman WA, Levine AD, Massari JV, et al,. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009; 183: 3170-6.
3. Arnold LM, Crofford LJ, Mease PJ, et al,. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008; 73: 114-20.
4. Schön MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-912.
5. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
6. Gottlieb AB,. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005; 4: 19-34.
7. Kauffman CL, Aria N, Toichi E, et al,. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123: 1037-44.
8. Kimball AB, Gordon KB, Langley RG, et al,. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144: 200-7.
9. Menter A, Papp KA, Tan H, et al,. Efficacy of tofacitinib, an oral Janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014; 13: 252-6.
10. Strober B, Buonanno M, Clark JD, et al,. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013; 169: 992-9.
11. West K,. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009; 10: 491-504.
12. Punwani N, Scherle P, Flores R, et al,. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67: 658-64.
13. Fridman JS, Scherle PA, Collins R, et al,. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 2011; 131: 1838-44.
14. Gibson UE, Heid CA, Williams PM,. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
15. Zaba LC, Cardinale I, Gilleaudeau P, et al,. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-94.
16. Haider AS, Lowes MA, Suàrez-Fariñas M, et al,. Cellular genomic maps help dissect pathology in human skin disease. J Invest Dermatol 2008; 128: 606-15.
17. Suwa T, Hogg JC, English D, van Eden SF,. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 2000; 279: H2954-60.
18. Maini RN, Taylor PC, Szechinski J, et al,. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.